Cryopreservation is often used as a means of storing haematopoietic progenitor cell-apheresis (HPC-A) product when it is collected as part of high-dose therapy for the treatment of haematological malignancies. Processing and cryopreservation of HPC-A is known to reduce the viability and the absolute number of CD34 + cells available for reinfusion. 1, 2 Therefore, a pilot vial (PV) containing a small aliquot of the same HPC-A material is usually cryopreserved and stored under the same conditions enabling enumeration and viability assessment on post-thaw HPC-A material without disturbing the primary infusion bag required for the transplantation. However, whether PV material can be used to assess other functional or phenotypic stem cell markers in HPC-A material following cryopreservation has not been fully investigated. We aimed to assess whether markers of viability, early apoptosis, DNA damage signalling and oxidative damage, together with CD34 + subset analysis performed similarly between PV and HPC-A material following cryopreservation.
Thirty matched pairs of HPC-A and PV were identified. Patient diagnoses included multiple myeloma (MM) (n = 10), nonHodgkin's lymphoma (NHL) (n = 11), Hodgkin's lymphoma (n = 2), AML (n = 3), CML (n = 1), 1 patient with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) and 2 with solid tumours. The nucleated cell concentration of the product for cryopreservation was 293 ± 17 × 10 6 /mL, expressed as mean ± s.e. HPC-A was plasma reduced and cryopreserved in a controlled rate freezer that was validated for both HPC-A and PV material, freezing at a rate of~1-3°C/min till − 50°C. Frozen products were then transferred to a liquid nitrogen vapour-phase tank (Chart Inc., Biomedical, Sydney, NSW, Australia) for storage. In each case, the PV was stored in the same cryopreservation cassette with its corresponding infusion bag. Because of the availability of paired clinical samples, only 4 out of 30 samples could be duplicated using a second PV. HPC-A and PV were simultaneously thawed to 37°C. Post-thaw CD45 + cell recovery and viable CD34 + cell number were assessed by 7-aminoactinomycin D (7-AAD) using the single-platform ISHAGE protocol, 3 one tube for each sample; intracellular aldehyde dehydrogenase (ALDH) activity was assessed by the ALDEFLUOR Assay kit (Stemcell Technology, Melbourne, VIC, Australia) 4,5 and stem cell subsets were assessed by CD133 6,7 and CD38. 8, 9 Mitochondrial membrane potential was assessed using 1,1′,3,3,3′-hexamethylindodicarbo-cyanine idodide (DilC5) staining as a marker of early apoptosis, 10,11 DNA damage was assessed using histone γH2AX as a marker of DNA double-stranded break formation 12 and intracellular reactive oxygen species (ROS) 13 was assessed using 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA). All assays were performed by flow cytometry. All markers, except CD45 + cell% recovery, are expressed as percentages of viable CD34 + cells. The means of all the markers obtained from paired samples of HPC-A and PV material were compared by Student's t-test.
A P-value o 0.05 was considered statistically significant. Data are expressed as mean ± s.e. There was no statistically significant difference between HPC-A and PV material in all markers assessed. For HPC-A vs PV material, post-thaw CD45 + cell% recovery was 72.3 ± 2.7 vs 72.7 ± 2.8 (P = 0.40), post-thaw CD34 + cell% recovery was 97.6 ± 0.7 vs 97.4 ± 0.6 (P = 0.40), viable CD34 + cells/μL was 5511.9 ± 1070.3 vs 5599.4 ± 1141.3 (P = 0.90) equating to viable CD34 + cells/kg of 6.0 ± 0.9 vs 6.3 ± 1.1 × 10 6 /kg (P = 0.78), CD133 + cell% was 63.6 ± 2.6 vs 60.3 ± 3.1 (P = 0.52) and CD38 − cell% was 17.2 ± 1.2 vs 17.6 ± 1.0 (P = 0.60), %ALDH activity was 52.7 ± 4.3 vs 60.4 ± 4.0 (P = 0.37); %DilC5 + staining was 46.1 ± 4.4 vs 55.7 ± 3.9 (P = 0.26); median fluorescence intensity (MFI) was 909 ± 99 vs 907 ± 85 (P = 0.52); %ROS activity was 70.4 ± 4.1 vs 71.0 ± 4.9; MFI was 12 245 ± 2268 vs 12 357 ± 2772 (P = 0.84), %γH 2 AX was 41.3 ± 7.5 vs 44.6 ± 7.4; MFI was 1092 ± 143 vs 932 ± 93 (P = 0.10).
Linear regression was performed to assess the relationship between paired samples of HPC-A and PV material. A P-value o0.05 was considered statistically significant; R 2 values are obtained with all intercepts taken through the origin (0, 0) ( Figure 1 
respectively). Correlations for CD38
− % (P o 0.005, R 2 = 0.58) and %DilC5 (P o 0.005, R 2 = 0.58) between HPC-A and PV material were more modest.
Correlation coefficients were determined to assess whether a relationship could be found between some subsets of viable CD34 + cells examined above in both HPC-A and PV material. A strong linear correlation was found between the non-apoptotic viable CD34
+ cell fraction as assessed by DilC5 staining and the viable stem cell marker ALDH in both HPC-A and PV material (R = 0.8 and 0.88, respectively, P o 0.005), whereas more modest correlations were found between DilC5 and ROS activity (R = 0.73 and 0.69, respectively, P o 0.005), and γH 2 AX expression and ROS (R = 0.57 and 0.55, respectively, P o0.005). For other subsets, examined R values were o0.5.
Markers were also compared between products obtained from NHL and MM patients. All results are expressed as mean ± s.e. There was a statistically significant increase in viable CD34 + CD38 − cell% in HPC-A product obtained from NHL vs MM patients (19.3 ± 2.0 vs 13.5 ± 1.1, respectively, P = 0.03). However, no difference could be found between viable CD34 + CD38 − cell% obtained from HPC-A vs PV material in NHL (19.3 ± 2.0 vs 18.3 ± 1.6, respectively, P = 0.84) or MM (13.5 ± 1.1 vs 15.2 ± 1.2, respectively, P = 0.5). There was no significant difference in other markers assessed between products obtained from NHL or MM patients.
In conclusion, cryopreserved HPC-A and PV material appears to behave similarly when assessed for a number of functional and phenotypic stem cell markers beyond enumerating CD34 + cell and assessing viability by 7-AAD using flow cytometry. PV material appears to be of acceptable quality and a research surrogate for more sophisticated testing of the contents of HPC-A that may have clinical relevance for assessment of short-and long-term engraftment potential following transplantation. Our results suggest that for a number of stem cell phenotypic markers and flow cytometric assessments of stem cell and subset quantification, viability, apoptosis and DNA damage, the results obtained from PV material are not significantly different from and appear to correlate with the results obtained from clinical HPC-A product. PV material may be a useful surrogate for assessment of the quality and nature of HSC in the infusion bag beyond enumerating CD34 + cells and assessment of post-thaw viability. 
